TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03405974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00857480
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
Study: NCT03613129
Drug: CT38
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion
Study: NCT04278820
Drug: TQA3526
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT04278820
Drug: Placebo to match TQA3526
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03923725
Drug: Artemether-lumefantrine + placebo (AL+PBO)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.
Study: NCT02218190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00837239
Drug: HuaChanSu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
Study: NCT00837239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml saline only administered as a 2 hour infusion by central line.
Study: NCT00468611
Drug: MBP8298
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg MBP8298 IV every six months for a period of two years
Study: NCT02404064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotics
Study: NCT03107611
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02414230
Drug: Drug: F 18 T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT01803646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for intratympanic injection
Study: NCT00675688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01354717
Drug: Brand Carac
Normalized name: Carace
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of actinic keratosis
Study: NCT01354717
Drug: Generic 0.5% 5-fluorouracil cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of actinic keratosis
Study: NCT01355497
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subject will receive matching placebo for the duration of the trial
Study: NCT03127436
Drug: Acarovac
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
Study: NCT00369278
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT00420342
Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH K 00641 A -Active study medication encapsulated tablet
Study: NCT04066478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03295760
Drug: Q10 Coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00668850
Drug: Regular human insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Study: NCT02244619
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
Study: NCT02244619
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
Study: NCT03335774
Drug: Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Study: NCT03335774
Drug: Placebo (Vehicle) Suppository (Nivagen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Study: NCT02434718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of 0.9% sodium chloride
Study: NCT01250002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will receive the same volume of saline infusion.
Study: NCT03795701
Drug: Saxenda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
Study: NCT01002443
Drug: Helicobacter pylori eradication
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
Study: NCT01002443
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
Study: NCT03531606
Drug: Mechnicov probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study: NCT03531606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study: NCT01320709
Drug: Piroxicam ( BAYl1902)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
Study: NCT01320709
Drug: Piroxicam ( BAYl1902)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
Study: NCT01320709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo (i.e., 4 placebo capsules)
Study: NCT01320709
Drug: Piroxicam ( BAYl1902)
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
Study: NCT02601703
Drug: Protopic® ointment, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply thin layer of ointment to affected area
Study: NCT00001575
Drug: Calcium-DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
Study: NCT00831792
Drug: TK1258
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
Study: NCT02605434
Drug: Accordion Pill™ Carbidopa/Levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
Study: NCT02605434
Drug: Sinemet®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
Study: NCT02605434
Drug: Placebo -AP-CD/LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AP-CD/LD capsule
Study: NCT02605434
Drug: Placebo- Sinemet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Sinemet tables
Study: NCT01199497
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
Study: NCT01199497
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00125957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00550992
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00550992
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00550992
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00550992
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00550992
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00550992
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00588965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
Study: NCT01120275
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02673463
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg once daily
Study: NCT02673463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually identical to spironolactone, once daily
Study: NCT00961363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02181348
Drug: placebo (edible oil)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01879371
Drug: Ibuprofen+caffeine FDC
Normalized name: caffeine / ergotamine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose
Study: NCT01879371
Drug: Ibuprofen (Nurofen Immedia®)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dose
Study: NCT01879371
Drug: Ibuprofen (Brufen®)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dose
Study: NCT01367912
Drug: estradiol tablet
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
Study: NCT01367912
Drug: estradiol tablet
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
Study: NCT00651378
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
Study: NCT03683043
Drug: Long GnRH agonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used.
Study: NCT00723268
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5MG Prednisolone per day for 3 months
Study: NCT00997282
Drug: OPC-262 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered once daily for 24 weeks
Study: NCT00997282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered once daily for 24 weeks
Study: NCT02945839
Drug: Preventative Medication (PM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
Study: NCT01972152
Drug: G-Pen(TM) 1 mg
Normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00872599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
Study: NCT00852865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day
Study: NCT03707678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
Study: NCT00132717
Drug: MK0653A (ezetimibe [+] simvastatin)
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00132717
Drug: Comparator: fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00132717
Drug: Comparator: lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00132717
Drug: Comparator: pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00132717
Drug: Comparator: rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00132717
Drug: Comparator: simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02559258
Drug: 0.1 mg/kg epsi-gam or placebo (6:2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single intravenous infusion on Day 1, infused over 30 minutes
Study: NCT02559258
Drug: 1.0 mg/kg epsi-gam or placebo (6:2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Study: NCT02559258
Drug: 3 mg/kg epsi-gam or placebo (6:2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single intravenous infusion on Day 1 infused over 60 minutes
Study: NCT02559258
Drug: 10 mg/kg epsi-gam or placebo (6:2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single intravenous infusion on Day 1 infused over 120 minutes
Study: NCT04311489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
Study: NCT02376036
Drug: MGD010
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
Study: NCT02376036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT02428088
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00265317
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Study: NCT04123444
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously infusion for 72 hours.
Study: NCT00801229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30, 50, 70 mg daily
Study: NCT02868099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03987763
Drug: IDP-122 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT03687476
Drug: VTS-270
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VTS-270 200 mg/mL administered as described in the arm group description.
Study: NCT03354273
Drug: PET MPI
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
Study: NCT03354273
Drug: SPECT MPI
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
Study: NCT03354273
Drug: Pharmacological stress agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
Study: NCT01597635
Drug: Dose 1 GSK2586881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GSK2586881 administered intravenously
Study: NCT01597635
Drug: Dose 2 GSK2586881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose GSK2586881 administered intravenously
Study: NCT01597635
Drug: Dose 3 GSK2586881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-High dose GSK2586881 administered intravenously
Study: NCT01597635
Drug: Dose 4 GSK2586881
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GSK2586881 administered intravenously
Study: NCT01597635
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously to match intervention
Study: NCT00096551
Drug: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00096551
Drug: Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00096551
Drug: Recombinant Fowlpox-GM-CSF
Normalized name: recombinant human GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02954848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets
Study: NCT02737475
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT00262639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
Study: NCT03141658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of placebo once daily for 6 days
Study: NCT00816829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate-matching placebo tablet
Study: NCT01751997
Drug: Transplants from 8/8-matched Unrelated donors
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11